Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
YMAB.US
id: 549, Created by Stan Vick Chase, Scout
Join Y-mAbs Therapeutics Negligence Case and recover your losses
How it works?
- We find Attorney for the Case
- Attorney files case on behalf of Investors
- You get updates and receive payout in case of success
Would it cost me anything?
- No, you do not pay anything out of your pocket neither to us, nor to Attorney
- Attorneys get % fee in case of success
- Platform charges service fee from Attorneys
What are the chances for success?
Every Case is unique, but statistically, 47% of Cases end up with a settlement.
Please see below recent successful cases:
How it works?
- We find Attorney for the Case
- Attorney files case on behalf of Investors
- You get updates and receive payout in case of success
Would it cost me anything?
- No, you do not pay anything out of your pocket neither to us, nor to Attorney
- Attorneys get % fee in case of success
- Platform charges service fee from Attorneys
What are the chances for success?
Every Case is unique, but statistically, 47% of Cases end up with a settlement.
Please see below recent successful cases:
On October 28, 2022, the FDA’s Oncologic Drugs Advisory Committee voted unanimously against approving the Y-mAbs’s (NASDAQ: YMAB) marketing application for omburtamab.
On this news, Y-mAbs’s stock price dropped over 59%, seriously damaging investors.
Earlier on October 26, 2022, the FDA released briefing documents expressing concerns that the Biologics License Application for the Company’s product candidate does not provide sufficient evidence of efficacy. The FDA cited the fact that the Company submitted data:
- from just a single center, single-arm trial;
- that additional analyses conducted by the FDA to examine bias and results found that differences in survival cannot be reliably attributed to omburtamab;
- and that the application does not include reliable response rate data to provide supportive evidence of the treatment effect of omburtamab.
On this news, YMAB's price fell over 27%.
Taking the nature of the issues into account, Investors have all reasons to suspect that the Company and its Leaders did not conduct the due performance of their work, which led to rejected application with the FDA.
Alleged Offence
Mismanagement,
Misleading Statements,
Malpractice,
Negligence,
Breach of Fiduciary duty,
Omissions
Suspected Party
Directors,
Management,
Government Authority,
Service Provider,
Research Entity
Security Type
Stocks
Trade Direction
Long
Shock Event Date
28 October 2022
Case number
23-CV-00431
Lead Plaintiff Deadline
21 March 2023
Court
Northern District of New York